The above RNA-seq analysis showed that ICAM1-DXd treatment not only directly ablates CCA cells but also improves tumor immune microenvironment via significantly upregulating the type I interferon signaling pathway in a PDX model. This evidence concerns the gene ICAM1 and neoplasm.